The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

The present invention relates to cells and methods for detecting compounds that affect G protein coupled receptor mediated conditions. The invention also relates to methods for treating adverse drug reactions, autoimmune disorders, and pruritus.

The present invention relates to monolithic bodies, uses thereof and processes for the preparation thereof. Certain embodiments of the present invention relate to the use of a monolithic body in the preparation of a radioactive substance, for example a radiopharmaceutical, as part of a microfluidic flow system and a process for the preparation of such a monolithic body.

The present invention relates to monolithic bodies, uses thereof and processes for the preparation thereof. Certain embodiments of the present invention relate to the use of a monolithic body in the preparation of a radioactive substance, for example a radiopharmaceutical, as part of a microfluidic flow system and a process for the preparation of such a monolithic body.

Provided are methods for labeling a pharmaceutical product to indicate the origin, and/or intended recipient, and/or a predetermined characteristic (e.g. geographic location) of an intended recipient of the pharmaceutical product. The methods include incorporating certain pharmaceutically inactive marker substances into the pharmaceutical product at manufacture.

Provided are methods for labeling a pharmaceutical product to indicate the origin, and/or intended recipient, and/or a predetermined characteristic (e.g. geographic location) of an intended recipient of the pharmaceutical product. The methods include incorporating certain pharmaceutically inactive marker substances into the pharmaceutical product at manufacture.

The present invention provides a D-serine transport modifier which is characterized by controlling the transport of D-serine into and out of cells by a D-serine transporter protein, a pharmaceutical composition which comprises the same as an active component and treats or prevents diseases relating to an increase or decrease in the amount of D-serine, and a screening method of substances that control the transport of D-serine. The present invention also provides a screening method of a D-serine transporter protein.

A human tissue stem cell in which a gene of interest is introduced into a gene locus of a stem cell marker gene.

An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

A method of producing a cell mass by three-dimensional culture of primary cancer cells having proliferative ability and properties of handleability, versatility, and high-throughput performance, in which a tumor tissue is used as a starting material, proliferation of cells such as fibroblasts other than cancer cells is inhibited, and the cell mass includes primary cancer cells as a main component. The object is achieved by providing a method of producing a cell mass by three-dimensional culture of primary cancer cells using a tumor tissue, including: a three-dimensional culture step of culturing cells obtained from the tumor tissue in a medium containing a 5% v/v or less extracellular matrix on a substantially low-adhesive cell culture substrate.